- Home
- CLPR vs CNTX Comparison
CLPR vs CNTX Comparison
Compare CLPR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- CNTX
- Stock Information
- Founded
- CLPR 2015
- CNTX 2015
- Country
- CLPR United States
- CNTX United States
- Employees
- CLPR 171
- CNTX N/A
- Industry
- CLPR Real Estate Investment Trusts
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- CNTX Health Care
- Exchange
- CLPR Nasdaq
- CNTX Nasdaq
- Market Cap
- CLPR 57.8M
- CNTX 60.7M
- IPO Year
- CLPR 2017
- CNTX 2021
- Fundamental
- Price
- CLPR $3.67
- CNTX $0.84
- Analyst Decision
- CLPR Sell
- CNTX Strong Buy
- Analyst Count
- CLPR 2
- CNTX 5
- Target Price
- CLPR N/A
- CNTX $6.50
- AVG Volume (30 Days)
- CLPR 212.1K
- CNTX 257.9K
- Earning Date
- CLPR 05-06-2025
- CNTX 05-07-2025
- Dividend Yield
- CLPR 10.30%
- CNTX N/A
- EPS Growth
- CLPR N/A
- CNTX N/A
- EPS
- CLPR N/A
- CNTX N/A
- Revenue
- CLPR $148,775,000.00
- CNTX N/A
- Revenue This Year
- CLPR N/A
- CNTX N/A
- Revenue Next Year
- CLPR N/A
- CNTX N/A
- P/E Ratio
- CLPR N/A
- CNTX N/A
- Revenue Growth
- CLPR 7.65
- CNTX N/A
- 52 Week Low
- CLPR $3.38
- CNTX $0.55
- 52 Week High
- CLPR $7.12
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- CLPR 44.08
- CNTX 56.99
- Support Level
- CLPR $3.60
- CNTX $0.80
- Resistance Level
- CLPR $3.82
- CNTX $0.89
- Average True Range (ATR)
- CLPR 0.23
- CNTX 0.11
- MACD
- CLPR 0.01
- CNTX 0.03
- Stochastic Oscillator
- CLPR 41.59
- CNTX 73.80
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.